Core Insights - The sequencing instrument market is experiencing significant changes with the launch of the DNBSEQ T7+ by BGI Genomics, which boasts a data output capacity exceeding 14Tb in 24 hours, making it one of the highest throughput and cost-effective clinical sequencing devices globally [1][5] - The competitive landscape for domestic sequencing instruments is intensifying, with various companies like Zhenmai Biology and Novogene launching innovative products to capture market share [2][6] Market Dynamics - The T7+ is now available for order, with immediate supply in mainland China and planned deliveries to Hong Kong, Macau, Taiwan, and overseas regions by the fourth quarter of 2025 [2] - Domestic sequencing instruments are gaining market share, with predictions indicating that by 2025, the market share of domestic brands could exceed 60% [3] - BGI Genomics reported a revenue of 1.114 billion yuan in the first half of 2025, a slight year-on-year decline of 7.9%, but with a 40% increase in instrument shipments [3] Competitive Landscape - The industry is witnessing a "razor-blade" model where instrument sales drive ongoing consumable revenue, making it crucial to capture installation volume for long-term value [4] - The rapid development of domestic sequencing instruments is accompanied by challenges such as intense price competition and the need for continuous R&D investment to maintain technological competitiveness [4][7] Global Expansion - Domestic sequencing companies are increasingly entering global markets, with BGI Genomics establishing over ten localized service centers abroad and Novogene's services reaching over 30 countries [8] - The gap between domestic devices and international brands is narrowing, indicating a new era driven by domestic innovation, AI integration, and multi-omics research [8]